Jefferies analyst Akash Tewari lowered the firm’s price target on Acelyrin (SLRN) to $12 from $15 and keeps a Buy rating on the shares after the company announced it recently identified dosing sequencing errors in izokibep’s ongoing Phase 2b/3 psoriatic arthritis, or PsA, trial involving CRO Fortrea (FTRE). While management highlighted that the overall powering wasn’t impacted, that the first four weeks of dosing weren’t affected, and that there are no additional safety issues related to this error, the firm “conservatively” assumes a two year delay for izokibep in PsA, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SLRN:
- Acelyrin says ‘disappointed’ by developments in Izokibep clinical program
- ACELYRIN, INC. Provides Update on Izokibep Clinical Development Program
- ACELYRIN, INC. Reports Third Quarter 2023 Financial Results and Recent Highlights
- Acelyrin appoints Patricia Turney as chief technical operations officer
- ACELYRIN, INC. to Report Third Quarter 2023 Financial Results and Corporate Update on November 7, 2023